Back to search

Article

NTRK, RET, ROS1, and ALK Gene Fusion in HER2 Immunohistochemistry 2+ Breast Carcinoma

2021-01-21

Abstract excerpt

<h4>Objective: </h4> HER2 immunohistochemistry (IHC) 2+ breast cancer patients need to determine the final HER2 status by fluorescence in situ hybridization (FISH) for selection of suitable treatment options. Although the HER2-positive cases can benefit from the anti-HER2 targeted therapy, it only made a small proportion of this group, so finding more targeted therapy methods is necessary. NTRK , RET , ROS1 and RE...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0056a9ec-08e0-516d-804e-d7a9134ad08e
DOI
10.21203/rs.3.rs-150274/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
NTRK, RET, ROS1, and ALK Gene Fusion in HER2 Immunohistochemistry 2+ Breast CarcinomaDOI 10.21203/rs.3.rs-150274/v1
Select a neighboring publication to make it the new centre.